Sarah E Hopkins1. 1. Division of Neurology, The Children's Hospital of Philadelphia, 3501 Civic Center Boulevard, Philadelphia, PA, 19104, USA. hopkinss1@email.chop.edu.
Abstract
PURPOSE OF REVIEW: Purpose of review Acute flaccid myelitis is a polio-like illness defined by the acute onset of flaccid paralysis in the setting spinal MRI demonstrating a longitudinal lesion in the gray matter of the cord. This paper aims to review the current state of knowledge and key clinical points for the diagnosis and management of acute flaccid myelitis. RECENT FINDINGS: Recent findings There were clusters of AFM noted in California and Colorado in 2014, with additional cases across the USA that year, and another spike in cases in 2016. Patients have been managed with classic treatments for transverse myelitis, but in general without benefit, although some colleagues have noted anecdotal improvement in individual patients. Our current practice at the Children's Hospital of Philadelphia is to initiate therapy with intravenous immunoglobulin (IVIG) upon recognition of acute flaccid myelitis in hopes of boosting humoral immunity, and to provide an emphasis on rehabilitation services, including physical and occupational therapy. There is some data that suggests a connection to the virus enterovirus D68 (EV D68), but there has been no definitive link. Publications regarding longer-term outcomes in these patients are early in development and, thus far, only provide data for 6 to 12 months from onset. Summary AFM is a serious illness with long-term consequences, and we have much to learn. Key areas in need of further investigation involve etiology, host susceptibilities, treatment options, and long-term outcome. Individual clinicians can assist in these efforts by the prompt reporting of cases of AFM to the US Centers for Disease Control and Prevention.
PURPOSE OF REVIEW: Purpose of review Acute flaccid myelitis is a polio-like illness defined by the acute onset of flaccid paralysis in the setting spinal MRI demonstrating a longitudinal lesion in the gray matter of the cord. This paper aims to review the current state of knowledge and key clinical points for the diagnosis and management of acute flaccid myelitis. RECENT FINDINGS: Recent findings There were clusters of AFM noted in California and Colorado in 2014, with additional cases across the USA that year, and another spike in cases in 2016. Patients have been managed with classic treatments for transverse myelitis, but in general without benefit, although some colleagues have noted anecdotal improvement in individual patients. Our current practice at the Children's Hospital of Philadelphia is to initiate therapy with intravenous immunoglobulin (IVIG) upon recognition of acute flaccid myelitis in hopes of boosting humoral immunity, and to provide an emphasis on rehabilitation services, including physical and occupational therapy. There is some data that suggests a connection to the virus enterovirus D68 (EV D68), but there has been no definitive link. Publications regarding longer-term outcomes in these patients are early in development and, thus far, only provide data for 6 to 12 months from onset. Summary AFM is a serious illness with long-term consequences, and we have much to learn. Key areas in need of further investigation involve etiology, host susceptibilities, treatment options, and long-term outcome. Individual clinicians can assist in these efforts by the prompt reporting of cases of AFM to the US Centers for Disease Control and Prevention.
Authors: Jan A Martin; Kevin Messacar; Michele L Yang; John A Maloney; Jennifer Lindwall; Terri Carry; Patricia Kenyon; Stefan H Sillau; Joyce Oleszek; Kenneth L Tyler; Samuel R Dominguez; Teri L Schreiner Journal: Neurology Date: 2017-06-14 Impact factor: 9.910
Authors: D B McCoy; J F Talbott; Michael Wilson; M D Mamlouk; J Cohen-Adad; Mark Wilson; J Narvid Journal: AJNR Am J Neuroradiol Date: 2016-12-15 Impact factor: 3.825
Authors: Keith Van Haren; Patrick Ayscue; Emmanuelle Waubant; Anna Clayton; Heather Sheriff; Shigeo Yagi; Rose Glenn-Finer; Tasha Padilla; Jonathan B Strober; Grace Aldrovandi; Debra A Wadford; Charles Y Chiu; Dongxiang Xia; Kathleen Harriman; James P Watt; Carol A Glaser Journal: JAMA Date: 2015 Dec 22-29 Impact factor: 56.272
Authors: J A Maloney; D M Mirsky; K Messacar; S R Dominguez; T Schreiner; N V Stence Journal: AJNR Am J Neuroradiol Date: 2014-11-20 Impact factor: 3.825
Authors: James J Sejvar; Adriana S Lopez; Margaret M Cortese; Eyal Leshem; Daniel M Pastula; Lisa Miller; Carol Glaser; Anita Kambhampati; Kayoko Shioda; Negar Aliabadi; Marc Fischer; Nicole Gregoricus; Robert Lanciotti; W Allan Nix; Senthilkumar K Sakthivel; D Scott Schmid; Jane F Seward; Suxiang Tong; M Steven Oberste; Mark Pallansch; Daniel Feikin Journal: Clin Infect Dis Date: 2016-06-17 Impact factor: 9.079
Authors: Patrick Ayscue; Keith Van Haren; Heather Sheriff; Emmanuelle Waubant; Paul Waldron; Shigeo Yagi; Cynthia Yen; Anna Clayton; Tasha Padilla; Chao Pan; John Reichel; Kathleen Harriman; James Watt; James Sejvar; William Allan Nix; Daniel Feikin; Carol Glaser Journal: MMWR Morb Mortal Wkly Rep Date: 2014-10-10 Impact factor: 17.586
Authors: Negar Aliabadi; Kevin Messacar; Daniel M Pastula; Christine C Robinson; Eyal Leshem; James J Sejvar; W Allan Nix; M Steven Oberste; Daniel R Feikin; Samuel R Dominguez Journal: Emerg Infect Dis Date: 2016-08 Impact factor: 6.883
Authors: P Texakalidis; D Xenos; N K Murthy; C L Karras; S J Trybula; M Behbahani; M G DeCuypere; S K Lam; T D Alden Journal: Childs Nerv Syst Date: 2022-01-04 Impact factor: 1.475
Authors: Margaret M Cortese; Anita K Kambhampati; Jennifer E Schuster; Zaid Alhinai; Gary R Nelson; Gloria J Guzman Perez-Carrillo; Arastoo Vossough; Michael A Smit; Robert C McKinstry; Timothy Zinkus; Kevin R Moore; Jeffrey M Rogg; Meghan S Candee; James J Sejvar; Sarah E Hopkins Journal: PLoS One Date: 2020-02-13 Impact factor: 3.240
Authors: Kazuteru Doi; Sei Haw Sem; Yasunori Hattori; Sotetsu Sakamoto; Kota Hayashi; Maria Angeles De la Red-Gallego Journal: JB JS Open Access Date: 2019-10-24